Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Partners With Marcadia For Injectable Pens To Treat Hypoglycemia

This article was originally published in The Pink Sheet Daily

Executive Summary

Already a leader in emergency kits, Lilly will support trials on a simpler device that doesn't require complex preparation.

You may also be interested in...



Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist

Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.

Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist

Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.

Roche Acquires Diabetes Biotech Marcadia

In the wake of its taspoglutide disappointment, Roche is acquiring privately-owned U.S. metabolic treatment maker Marcadia Biotech for an undisclosed sum.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS070829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel